360° SearchNetwork Hot Spots Trends Time Series

Psoriatic Arthritis

Type: Keyphrase

Name: Psoriatic Arthritis

First reported 12 hours ago - Updated 12 hours ago - 1 reports

RAPID™-PsA study highlights burden of psoriatic arthritis

UCB has announced new data from the RAPIDTM-PsA study on certolizumab pegol in the treatment of moderate to severe psoriatic arthritis (PsA) at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain. Results showed that certolizumab ... [Published Hospital Pharmacy Europe - 12 hours ago]

Entities: Certolizumab Pegol, Psoriatic Arthritis, Encumbrance, Patient, Placebo

First reported Jun 16 2013 - Updated 15 hours ago - 1 reports

Lipids Linked to Active Psoriatic Arthritis (CME/CE)

MADRID (MedPage Today) -- High disease activity in psoriatic arthritis is associated with elevated total cholesterol and triglycerides, adding to a growing body of evidence linking psoriatic arthritis metabolically with dyslipidemia and obesity, a researcher ... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 16 2013]

Entities: Psoriatic Arthritis, Lipids, Triglycerides, Cholesterol

First reported Jun 14 2013 - Updated Jun 14 2013 - 3 reports

New Data on UCB's Cimzia - Analyst Blog

UCB ( UCBJF ) recently presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia. The data was presented at the European League Against Rheumatism (EULAR) Congress.According to the recent findings, active psoriatic arthritis (PsA) and ... [Published Nasdaq - Jun 14 2013]

Entities: Certolizumab Pegol, Placebo, Psoriatic Arthritis, Phase III

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

University of California San Diego

Long-term apremilast 'effective' in psoriatic arthritis

A novel drug called apremilast appears to be effective when used for extended periods of time to treat psoriatic arthritis, according to phase-III clinical trial data presented at the annual congress of the European League Against Rheumatism (EULAR).Apremilast ... [Published Arthritis Research UK - Jun 14 2013]

Entities: Psoriatic Arthritis, Patient, Placebo, University of California San Diego, Drugs

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Celgene Corporation

Apremilast Data Presented by Celgene Zacks

Celgene Corporation (CELG) recently announced results from a phase III study (PALACE 3: n=495) on its pipeline candidate apremilast. The study evaluated apremilast in patients suffering from psoriatic arthritis at 20 mg and 30 mg dosages (twice daily). ... [Published Yahoo! Finance - Jun 14 2013]

Entities: Celgene Corporation, Psoriatic Arthritis, Phase III, Psoriasis

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Apremilast Eases Psoriatic Arthritis (CME/CE)

MADRID (MedPage Today) -- A year of treatment with the new oral drug, which targets inflammatory mediators, led to significant long-term reduction in disease activity among patients with psoriatic arthritis, a researcher reported here. ... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 14 2013]

Entities: Psoriatic Arthritis, Madrid, Patient

First reported Jun 13 2013 - Updated Jun 13 2013 - 3 reports

CELG Presents Positive Long-term Data Zacks

Celgene Corporation (CELG) recently announced encouraging results from a phase III study (PALACE 1) on its pipeline candidate apremilast. The study evaluated apremilast for 52 weeks in patients suffering from psoriatic arthritis at 20 mg and 30 mg dosages. ... [Published Yahoo! Finance - Jun 13 2013]

Entities: Celgene Corporation, Psoriatic Arthritis, Psoriasis, Patient

First reported Jun 12 2013 - Updated Jun 13 2013 - 5 reports

Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer

Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic ... [Published The Rose Sheet - Jun 13 2013]

Entities: Phase III, Amgen Inc, Ovarian Cancer

First reported Jun 13 2013 - Updated Jun 13 2013 - 2 reports

New PhIII data raises hopes for Celgenes apremilast

Celgene has unveiled late-stage data showing that its experimental drug apremilast induced "meaningful improvements" in the signs and symptoms of psoriatic arthritis in the long term, adding further weight to the package of data being used to seek regulatory ... [Published Big News Network - Jun 13 2013]

Entities: Celgene Corporation, Psoriatic Arthritis, Drugs

First reported Jun 13 2013 - Updated Jun 13 2013 - 2 reports

[Articles] Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments. ... [Published The Lancet online - Jun 13 2013]

Entities: Ustekinumab, Psoriatic Arthritis, Phase III, Patient

First reported Jun 11 2013 - Updated Jun 12 2013 - 19 reports

New Data Improves Sales Outlook For Celgene's Apremilast

Home » Blogs » SUMMIT, NJ (TheStreet) -- Celgene's strong stock performance this year started with the release of bullish, long-term (2017) guidance in early January. While Street estimates are generally close to Celgene's own forecasts, the biggest difference ... [Published BioPortfolio - Jun 12 2013]

Entities: Celgene Corporation, Psoriatic Arthritis, Biology

First reported Jun 12 2013 - Updated Jun 12 2013 - 2 reports

J&J’s Stelara Shows Progress In Arthritis Treatment and 2 Other Dow Movers to Watch

Johnson & Johnson ( NYSE:JNJ ): Current price $83.82According to data being presented at a medical meeting in Europe, Johnson & Johnson’s Stelara exhibited significant improvement in signs and symptoms of psoriatic arthritis through 52 weeks of treatment ... [Published Wall St. Cheat Sheet - Jun 12 2013]

Entities: Stelara, Johnson & Johnson, WildTangent Inc, Arthritis

Quotes

...in turn could lead to a financial burden for both patients and society," said Professor Dafna Gladman, Toronto Western Research Institute, Canada. "To date, there are few data on work and household productivity among patients with PsA. The RAPID™-PsA study offers additional insight on the burden of PsA. In this study, patients treated with certolizumab pegol reported improved work and household productivity as well as improvements in outcomes such as fatigue and pain, which can help patients cope with everyday activities."

RAPID™-PsA study highlights burden of psoriatic arthritis [Published Hospital Pharmacy Europe - 12 hours ago]

"These results show that apremilast may become a potential therapy for psoriatic arthritis patients."

Long-term apremilast 'effective' in psoriatic arthritis [Published Arthritis Research UK - Jun 14 2013]

"These data show that our candidates, in combination with existing biomarkers, could help close the diagnostic gap in RA. In addition, significant associations with inflammatory factors and the presence of erosions indicate a tangible prognostic potential" De Winter concluded. 1.De Winter L et al., New autoantibodies as biomarkers for early and seronegative rheumatoid arthritis [abstract]...

Novel biomarkers improve diagnosis in rheumatoid arthritis [Published EurekAlert! - Jun 14 2013]

...psoriatic arthritis and Abraxane in pancreatic cancer should sustain good growth momentum," stated Michael Levesque, Moody's Senior Vice President. "If pipeline execution is combined with conservative financial policies and healthy credit ratios, Moody's could upgrade Celgene's credit ratings" continued Levesque

Moody's Boosts Outlook on Celgene (CELG) to Stable; Affirms Ratings [Published Street Insider - Jun 12 2013]

More Content

sort by: Date \| Relevance
RAPID™-PsA study highlights burden of psoriatic... [Published Hospital Pharmacy Europe - 12 hours ago]
Eli Lilly's CEO Presents at Goldman Sachs Healt... [Published Seeking Alpha - 16 hours ago]
Lipids Linked to Active Psoriatic Arthritis (CM... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 16 2013]
BMS and Simcere Collaborate to Develop Subcutan... [Published Pharma-Mag - Jun 15 2013]
New Data on UCB's Cimzia - Analyst Blog [Published Nasdaq - Jun 14 2013]
New Data on UCB's Cimzia - Analyst Blog [Published Quote.com Canada - Jun 14 2013]
New Data on UCB's Cimzia [Published Yahoo! Finance - Jun 14 2013]
Long-term apremilast 'effective' in psoriatic a... [Published Arthritis Research UK - Jun 14 2013]
Finally, Lasting Comfort For Psoriasis Patients [Published Prlog - Jun 14 2013]
Apremilast Data Presented by Celgene Zacks [Published Yahoo! Finance - Jun 14 2013]
East Coast Life Sciences Roundup: Agios, Ludwig... [Published Xconomy - Jun 14 2013]
Novel biomarkers improve diagnosis in rheumatoi... [Published EurekAlert! - Jun 14 2013]
Apremilast Eases Psoriatic Arthritis (CME/CE) [Published MedPageToday.com - medical news plus CME for ph ... - Jun 14 2013]
4 Healthcare Stock Stories Getting Notice On Th... [Published Wall St. Cheat Sheet - Jun 13 2013]
4 Healthcare Stock Stories Getting Notice On Th... [Published Wall St. Cheat Sheet - Jun 13 2013]
CELG Presents Positive Long-term Data Zacks [Published Yahoo! Finance - Jun 13 2013]
Wal-Mart’s Shift In Hiring Practices, FedEx Fac... [Published Wall St. Cheat Sheet - Jun 13 2013]
Wal-Mart’s Shift In Hiring Practices, FedEx Fac... [Published Wall St. Cheat Sheet - Jun 13 2013]
STELARA® Phase 3 Study Published In The Lancet ... [Published PR Newswire: Health - Jun 13 2013]
Celgene Reports Phase III Apremilast Data at EULAR [Published Pharma-Mag - Jun 13 2013]
Celgene Reports Results From PALACE 3 - Quick F... [Published RTTNews.com - Jun 13 2013]
Data from Phase III Randomized Controlled Study... [Published Enhanced Online News - Jun 13 2013]
Data from Phase III Randomized Controlled Study... [Published Business Wire Health News - Jun 13 2013]
New study shows treatment with brodalumab demon... [Published News-Medical.Net - Jun 13 2013]
New PhIII data raises hopes for Celgenes apremi... [Published Big News Network - Jun 13 2013]
Amgen’s Trebananib Meets First Phase III Goal I... [Published The Rose Sheet - Jun 13 2013]
[Articles] Efficacy and safety of ustekinumab i... [Published The Lancet online - Jun 13 2013]
[Comment] Ustekinumab for psoriatic arthritis: ... [Published The Lancet online - Jun 13 2013]
New PhIII data raises hopes for Celgene's aprem... [Published Pharma Times - Jun 13 2013]
Pipeline vs. Expiring Patents: Eli Lilly’s Future [Published YCharts - Jun 12 2013]

Blogs

sort by: Date \| Relevance
BMS and Simcere Collaborate to Develop Subcutan... [Published Pharma-Mag - Jun 15 2013] Bristol-Myers Squibb and China’s Simcere Pharmaceutical Group are to collaborate on the development and commercialisation in China of a subcutaneous formulation of the US drug firm’s fusion protein drug Orencia® (abatacept), for treating rheumatoid ...
4 Healthcare Stock Stories Getting Notice On Th... [Published Wall St. Cheat Sheet - Jun 13 2013] Eli Lilly and Company ( NYSE:LLY ): Closing price $ 51.85On Thursday, Lilly and Incyte Corporation announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA evaluation of baricitinib in patients suffering ...
4 Healthcare Stock Stories Getting Notice On Th... [Published Wall St. Cheat Sheet - Jun 13 2013] Eli Lilly and Company ( NYSE:LLY ): Closing price $51.85 On Thursday, Lilly and Incyte Corporation announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA evaluation of baricitinib in patients suffering ...
Wal-Mart’s Shift In Hiring Practices, FedEx Fac... [Published Wall St. Cheat Sheet - Jun 13 2013] Wal-Mart ( NYSE:WMT ): The retail giant seems to be padding its payroll with temporary workers in recent months, marking the first time that the company has done so outside of the holiday season. A Reuters survey of 52 stores run by the largest U.S. private ...
Wal-Mart’s Shift In Hiring Practices, FedEx Fac... [Published Wall St. Cheat Sheet - Jun 13 2013] Wal-Mart ( NYSE:WMT ): The retail giant seems to be padding its payroll with temporary workers in recent months, marking the first time that the company has done so outside of the holiday season. A Reuters survey of 52 stores run by the largest U.S. ...

Press Releases

sort by: Date \| Relevance
STELARA® Phase 3 Study Published In The Lancet ... [Published PR Newswire: Health - Jun 13 2013]
Data from Phase III Randomized Controlled Study... [Published Business Wire Health News - Jun 13 2013]
Signs and Symptoms of Psoriatic Arthritis Signi... [Published Business Wire Health News - Jun 12 2013]
National Psoriasis Foundation awards six resear... [Published PR Newswire: Policy & Public Interest - Jun 04 2013]
Paractin Featured in New Medical Book [Published PR.com Press Releases - May 24 2013]